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Background: Over recent years a number of novel therapies have shown promise in advanced renal cell carcinoma
(RCC). Internationally the standard of care of first-line therapy is sunitinib™, after a clear survival benefit was
demonstrated over interferon-α. Convention dictates that sunitinib is continued until evidence of disease
progression, assuming tolerability, although there is no evidence that this approach is superior to intermittent
periods of treatment. The purpose of the STAR trial is to compare the standard treatment strategy (conventional
continuation strategy, CCS) with a novel drug free interval strategy (DFIS) which includes planned treatment breaks.
Methods/Design: The STAR trial is an NIHR HTA-funded UK pragmatic randomised phase II/III clinical trial in the
first-line treatment of advanced RCC. Participants will be randomised (1:1) to either a sunitinib CCS or a DFIS. The
overall aim of the trial is to determine whether a DFIS is non-inferior, in terms of 2-year overall survival (OS) and
quality adjusted life years (QALY) (averaged over treatment and follow up), compared to a CCS. The QALY primary
endpoint was selected to assess whether any detriment in terms of OS could be balanced with improvements in
quality of life (QoL). This is a complex trial with a number of design challenges, and to address these issues a
feasibility stage is incorporated into the trial design. Predetermined recruitment (stage A) and efficacy (stage B)
intermediary endpoints must be met to allow continuation to the overall phase III trial (stage C). An integral
qualitative patient preference and understanding study will occur alongside the feasibility stage to investigate
patients’ feelings regarding participation or non-participation in the trial.
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Discussion: The optimal duration of continuing sunitinib in advanced RCC is unknown. Novel targeted therapies
do not always have the same constraints to treatment duration as standard chemotherapeutic agents and currently
there are no randomised data comparing different treatment durations. Incorporating planned treatment breaks has
the potential to improve QoL and cost effectiveness, hopefully without significant detriment on OS, as has been
demonstrated in other cancer types with other treatments.
Trial Registration: Controlled-trials.com ISRCTN 06473203
Keywords: Renal cancer, Sunitinib, Intermittent treatment, Quality of life, Quality adjusted life years, Health economicsBackground
Renal cell carcinoma
Renal cell carcinoma (RCC) constitutes only 3% of adult
malignancies, but is the sixth leading cause of cancer-
related death due to the lack of effective therapy for lo-
cally advanced and metastatic disease.
The strategy of targeting angiogenic pathways has pro-
duced positive results in advanced RCC. Tyrosine kinase
inhibitors (TKIs), e.g. sunitinib and sorafenib, and
monoclonal antibodies, e.g. bevacizumab with IFNα,
have produced improvements in terms of progression
free survival (PFS) and overall survival (OS). Sunitinib
(SutentTM) selectively targets multiple protein receptor
tyrosine kinases including vascular endothelial growth
factor receptor and platelet-derived growth factor re-
ceptor. This inhibits tumoural delivery of blood and
nutrients required for growth, which ultimately leads to
cancer cell death. Sunitinib also has a direct inhibitory
effect on tumour cells [1].
The landmark sunitinib trial in RCC was a double-
blind randomised controlled trial of 750 patients (ECOG
performance status 0 or 1) with metastatic RCC which
compared sunitinib to IFNα as first-line therapy [2]. The
primary endpoint was PFS and the trial was unblinded
after a second interim analysis demonstrated significant
benefit in patients treated with sunitinib. Updated
results were published in 2009 and demonstrated a me-
dian PFS of 11 months with sunitinib and 5 months with
IFNα in the intention-to-treat population (p<0.001) [3].
The OS was 26.4 months with sunitinib and 21.8 months
with IFNα (HR 0.821; 95% confidence intervals [CI]=0.673-
1.001, p=0.051), however this difference is likely to be
an underestimate due to significant crossover from
IFNα to sunitinib after unblinding. Sunitinib was also
associated with improved response rates over IFNα
(47% vs 12%).
Sunitinib was approved by NICE in 2009 for UK use
in the first-line treatment of advanced RCC in patients
with a good performance status (ECOG 0 or 1) until evi-
dence of disease progression or unacceptable toxicity
[4]. This was after reappraisal under the specific ‘end-of-
life’ criteria as it had not previously been approved under
standard NICE decision-making criteria.Sunitinib is associated with a significant side effect
burden. The landmark first-line trial reported that 19%
of patients discontinued sunitinib due to adverse events
(AEs) and 50% of patients required a dose reduction [3].
In the sunitinib open access program 8% of patients dis-
continued drug due to serious adverse events (SAEs)
and a further 30% had dose reductions due to toxicity
[5]. Commonly reported AEs included hypertension
(12%), fatigue (11%), diarrhoea (9%) and hand-foot syn-
drome (9%) [3]. The longer-term impact of sunitinib-
associated toxicities are also recognised to be increas-
ingly important as patients are living longer [6].
Intermittent anti-cancer treatment strategies
There is increased interest in drug-free interval stra-
tegies (DFIS) in oncology with evidence that these
approaches are associated with reduced toxicity and
improved quality of life (QoL), without significantly
compromising survival benefits. This approach is most
studied in colorectal cancer (CRC), where there is evi-
dence that planned treatment breaks (a DFIS) can be
utilised with no, or a minimal, OS deficit, but with an
associated advantage in terms of improved QoL [7-10].
OPTIMOX1 compared 6 cycles of FOLFOX7 (three
weekly bolus oxaliplatin, 5-fluorouracil [5FU] and folinic
acid [FA]) followed by 5FU/FA alone (for up to 24 weeks)
before re-introduction of oxaliplatin, to FOLFOX4 (two
weekly bolus oxaliplatin, 5FU and FA) until progression,
in 623 patients with metastatic CRC [9]. The results
from this trial demonstrated that duration of disease
control was similar between both arms (10.6 and
9.0 months respectively), as were PFS and OS. Import-
antly almost 60% of patients on the intermittent arm did
not have oxaliplatin reintroduced at the appropriate
timepoint, but those that did tended to have a better
outcome [11]. Not reintroducing drugs as per protocol
recommendation has been a significant issue in a num-
ber of the trials investigating a DFIS. The subsequent
OPTIMOX2 trial compared complete breaks from
chemotherapy with continued 5FU/FA until progression,
but unfortunately was stopped prematurely after recruit-
ment of only 216 of the planned 600 patients as the
standard arm became obsolete due to the availability
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strated improved duration of disease control (13.1 vs
9.2 months) and OS (23.8 vs 19.5 months) in the con-
tinuous arm, however there have been criticisms levied
at the trial design, in particular the primary endpoint of
duration of disease control, as treatment for progressive
disease was not mandated until the disease reached
baseline size, not at the time of initial progression com-
pared to best response as is standard practice. The sta-
tistical plan was also not adapted to account for the
reduced sample size from 600 to 216. This prevents de-
finitive conclusions being drawn from the results [7].
In the UK this concept of planned treatment breaks
was further investigated with the large randomised
COIN trial [10]. In this study 1639 patients receiving
oxaliplatin plus fluoropyrimidine-based chemotherapy
were randomly assigned (1:1) to continuous chemothe-
rapy until progression (arm A) or intermitted chemo-
therapy (arm C). In arm C, patients at 12 weeks who
were responding, or who had stable disease, stopped
chemotherapy until evidence of clinical or radiological
disease progression. Whilst the results were unable to
confirm non-inferiority of intermittent chemotherapy
(the continuous arm demonstrated an improvement in
OS of 1.4 months, HR 1.084, 80%CI 1.008-1.165), it was
concluded that intermittent treatment is a reasonable
option in fully informed patients due to the reductions
in cumulative toxicities and improvements in QoL,
traded off with minimal detriment in terms of OS.
Treating patients with CRC with pre-planned chemo-
therapy breaks remains standard practice in many cen-
tres internationally.
A number of smaller studies provide further support
for a sunitinib DFIS. One study included 23 patients
with metastatic RCC who had previously responded to
sunitinib, and then received alternative therapies at pro-
gression (median duration 6.7 months) who were then
re-challenged with sunitinib at the time of further pro-
gression. In this cohort a second sunitinib-related PFS of
7.2 months (median) was achieved [12]. Importantly no
additional or increased toxicities were observed on re-
challenge. Another small retrospective study reported
the effects of stopping sunitinib therapy in 11 patients
who had had a complete response, with or without sur-
gical metastectomy following response to sunitinib [13].
At median follow up of 8.5 months, disease had recurred
in 5 patients, but in all cases re-introduction of sunitinib
was effective in regaining disease control.
There is also one randomised phase II study in which
202 patients with metastatic RCC were treated with sor-
afenib (an alternative TKI). After 12 weeks of sorafenib,
the 65 patients with stable disease (SD) were randomly
assigned to continue sorafenib (n=32) or placebo (n=33).
At 24 weeks 50% of patients continuing sorafenib wereprogression-free compared with 18% of placebo-treated
patients (p=0.0077), however, when sorafenib was re-
administered in 28 of the placebo-treated patients with
disease progression, further progression was delayed for
a median of 24 weeks. The researchers concluded that
intermittent treatment with sorafenib resulted in com-
parable median summative PFS as for those patients re-
ceiving continuous sorafenib [14]. This suggests that
patients were not disadvantaged from a brief period of
placebo treatment, providing further ethical support for
the design of the STAR trial.
At present there is no clearly defined optimal treat-
ment strategy for many targeted therapies, and research
in this field is crucial both for patients in terms of QoL
and for the National Health Service (NHS) in terms of
cost-effectiveness. Regarding sunitinib in advanced RCC,
evidence for the cost-effectiveness is currently poor and
standard decision criteria did not support its implemen-
tation in the NHS. The STAR trial will address the need
to gather robust evidence on the costs, QoL and clinical
outcomes of sunitinib using both a DFIS and a conven-
tional continuation strategy (CCS). If successful, the de-
sign may be applicable to other drugs across a wide
range of diseases.
Methods/design
Trial aims and objectives
This trial will determine whether by utilising a sunitinib
DFIS in advanced RCC, survival benefits can be main-
tained, whilst other important outcomes such as QoL
and cost-effectiveness, can be improved, compared to
utilising a sunitinib CCS. The STAR trial is a three-stage
phase II/III trial with stages A and B incorporated into
the phase II trial component and Stage C incorporated
into the phase III trial (which includes participants from
all 3 stages).
Overall primary objectives
 To determine whether a sunitinib DFIS is non-
inferior in terms of 2-year OS and quality-adjusted
life years (QALYs) (averaged over trial recruitment
and follow-up) compared to a sunitinib CCS, in
patients with locally advanced and/or metastatic
clear cell RCC.
Oncological treatments for patients with incurable dis-
ease require assessment using standard measures of effi-
cacy, such as survival. It is however recognised that
other measures must also be taken into consideration in-
cluding QoL and cost, particularly in the context of the
economic constraints of the NHS. When seeking ap-
proval from NICE for a new treatment, all of these out-
comes are considered. A composite co-primary endpoint
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was selected as a primary outcome measure to more ac-
curately assess whether any detriment in survival could
be balanced with improvements in QoL and cost-effect-
iveness. Limitations of the previously reported QoL data
relating to advanced RCC means significant uncertainty
remains about the profile, timing and magnitude of the
QoL impact of sunitinib treatment, hence OS has been
retained as a co-primary endpoint.
Stage specific primary objectives
Stage A: To establish the feasibility of performing the
phase III trial in terms of average recruitment between
months 10–21 (inclusive). This is to ensure that
sufficient participants can be recruited to enable its
completion in a timely manner, assuming continuation
to stage C.
Stage B: To provide initial efficacy data by comparing
time to strategy failurea (TSF) in both arms and test for
non-inferiority between the approaches to assess
comparability.
Stage C: 2 year OS and QALY averaged over study
recruitment and follow up
Secondary objectives
The secondary objectives are to evaluate how utilisation
of DFIS compared to utilisation of a CCS impacts on:
 Summative Progression Free Interval (SPFI)b
 Time to Strategy Failure (TSF)
 Toxicity (CTCAE v.4.0)
 QoL
 Cost-effectiveness
 Progression free survival (PFS)
Trial population
The STAR trial population is planned to be inclusive of
all patients who would be eligible to receive sunitinib in
the UK, in accordance with current NICE guidance and
its marketing licence. Suitable patients will be male or
female, aged ≥ 18 years old, with a histologically con-
firmed clear cell inoperable locally advanced or metastatic
RCC, having had no prior systemic therapy for advanced
disease. Patients will be ECOG performance status 0–1
and be required to have uni-dimensionally measurable
disease as per RECIST criteria. Patients will be required to
have appropriate haematological and biochemical para-
meters and to provide written informed consent.
Allowable situations include patients with either pri-
mary renal cancer in-situ or having undergone a pre-
vious nephrectomy, patients with previously diagnosed
brain metastases treated with complete surgical resec-
tion or gamma knife therapy with no subsequentevidence of progression (patients treated with whole
brain radiotherapy are not eligible) and patients previ-
ously treated on the SORCE sorafenib adjuvant trial,
providing they did not receive sorafenib. Patients are
also eligible to participate in the STAR trial having had
previous radiotherapy and/or previous/ongoing bispho-
sphonates for the treatment of symptomatic bony
metastasis.
Patients are not eligible to participate in the STAR trial
with pulmonary or mediastinal disease causing obstruc-
tion and/or haemoptysis, if they have an estimated life
expectancy of <6 months, if they have any known con-
traindications to sunitinib (including hypersensitivity) or
have had any previous treatment with sunitinib or other
tyrosine kinase inhibitor (including in the adjuvant set-
ting). Patients will also be ineligible to participate if they
are taking any concomitant medications known to sig-
nificantly affect the activity or pharmacokinetics of suni-
tinib or if they have poorly controlled hypertension
despite maximal medical therapy. Patients with any
other serious medical or psychiatric condition, which in
the opinion of the investigator could affect participation
in the STAR trial will also be excluded.Trial design
This is a pragmatic UK, multi-centre two-arm, rando-
mised (1:1) controlled, multi-stage, open-label phase II/
III trial in patients with inoperable locally advanced or
metastatic clear cell renal cell cancer to evaluate the use
of a sunitinib DFIS compared to the sunitinib CCS (see
Figure 1). It is a particularly appropriate trial in the UK
due to the need to develop treatment strategies that will
allow patients access to treatments, which are delivered
in the most beneficial and cost-effective way in the NHS.
There are design challenges relating to this trial and a
multi-stage approach has been utilised to optimise the
effectiveness of the design in terms of time and sample
size. The trial must meet pre-determined intermediary
endpoints in stages A and stage B for recruitment to
continue into stage C. Achievement of stage-specific
endpoints will be assessed by an independent data moni-
toring and ethics committee (DMEC).
Sample size
In total, for all 3 stages, 1000 patients will be required
(allowing for a 10% drop-out), 210 in stages A/B (phase
II), and a further 790 in stage C (phase III). Stages A/B
will be performed in 13 UK sites, and assuming conti-
nuation to stage C, then the trial will be opened up to a
further 26 sites. The sample size is based on the co-
primary endpoints, however it will also be adequate to
obtain meaningful conclusions regarding the key sec-
ondary endpoints e.g. QoL.
Figure 1 Summary of the STAR trial.
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incorporates a random element will be used to ensure that
treatment groups are well balanced for the following fac-
tors: Motzer prognostic group [15] (favourable risk (0 fac-
tors) vs. intermediate risk (1–2 factors) vs poor risk (≥ 3
factors)), trial site, sex, age (< 60 years vs. ≥ 60 years), dis-
ease status at randomisation (locally advanced vs. meta-
static) and whether or not the patient has had a previous
nephrectomy.
Blinding
Blinding of the study was considered, acknowledging
that this would be preferable scientifically, particularly in
respect of patient reported outcomes. However, due tothe well-recognised toxicity profile of sunitinib, and the
costs involved, it was decided not to blind this trial. Ac-
curate radiological evaluations will be fundamental to
the stage B endpoint (TSF), and for this reason all radio-
logical evaluations in the initial two stages (A and B) will
be performed centrally. Due to the need for the radiolo-
gist to be certain which scan they are comparing subse-
quent scans to (the baseline scan will change in the
DFIS arm) it was not possible to maintain the blind of
the central radiologist. The central radiology report,
not the local report, will be used to determine whether
sunitinib is stopped, continued or recommenced (de-
pending on individual participant arm and current
situation).
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Consideration was given to the optimal timing for ran-
domisation, either prior to receiving any treatment
(baseline), or just prior to participants taking up their
randomisation strategy (DFIS/CCS) (this will be at
6 months for most patients). Randomisation was decided
to be performed at baseline and participants’ feelings
regarding this will be further explored in a qualitative
participant preference and understanding study. There is
supportive data demonstrating higher patient uptake of
allocated arm if randomisation occurred at baseline from
a colorectal trial [16] and a lung cancer trial [17]. This
decision was also reinforced from a number of consulta-
tions with patients taking sunitinib regarding their ran-
domisation timing preferences.
Recruitment
Participant recruitment is planned over 21 months in
stages A/B, and then to seamlessly continue for a further
33 months assuming continuation to stage C, with a
number of other centres opening to recruitment in stage
C. All participants will be followed up until 2 years after
the last participant is randomised. The duration of the
trial is expected to be 84 months including set up, re-
cruitment, follow-up and analysis. Recruitment com-
menced in January 2012.
Baseline investigations
Baseline investigations are planned to be in line with
standard UK practice for patients receiving sunitinib
and, apart from a pregnancy test in appropriate female
participants, there are no other trial-specific screening
investigations.
Intervention
Participants in both arms of the trial will receive suniti-
nib which will be administered orally at 50 mg once
daily on days 1 to 28 of the standard 42 day cycle. Daily
doses may be modified for toxicity to 37.5 mg and
25 mg, in line with standard clinical practice.
After completion of at least 4 cycles of sunitinib and
maximal radiological response, participants will take up
their randomisation arm. Participants randomised to the
control arm will continue sunitinib according to the
CCS i.e. continuing treatment until evidence of disease
progression or toxicity precluding continuation. Partici-
pants randomised to the experimental arm will continue
according to the DFIS i.e. they will temporarily stop
sunitinib (a planned treatment break). Participants will
remain off treatment until radiologically-confirmed evi-
dence of disease progression. At this time sunitinib will
be restarted following the same scheduling and dose as
before. In participants who regain further disease con-
trol, after completion of a minimum of 4 cycles ofsunitinib and maximal radiological response, further
planned treatment breaks will be implemented.
All participants will continue with their allocated suni-
tinib treatment strategy as per protocol (with dose
reductions as required) until radiologically-confirmed
disease progression occurs whilst taking sunitinib, un-
acceptable toxicity or participant choice to stop per
protocol treatmentFollow-up
The planned duration of the trial follow-up is until
2 years after the last participant is randomised. During
continuation of protocol-defined treatment (sunitinib as
per CCS or DFIS) six-weekly clinical assessments and
twelve-weekly radiological assessments will occur, in line
with standard practice. Where protocol-defined treat-
ment has permanently stopped, details of any subse-
quent treatment received for renal cancer and the
participant’s status will be collected at six months and
then on an annual basis.Data collection and management
All protocol-required information will be entered onto
paper case report forms (CRFs) at each site. Initial par-
ticipant details will be collected on a baseline CRF, and
an additional CRF will be completed at each clinical
visit, including details of toxicities relating to sunitinib.
Participants will also complete several QoL question-
naires (EQ-5DTM/EQ-VAS, FACT-G and FKSI) and a
medical resource utilisation (MRU) questionnaire at
each visit. During months 6–12 of a participant being on
the trial they will also be asked to complete two-weekly
EQ-5DTM/EQ-VAS questionnaires at home. Text and
email reminders will be offered to assist with compli-
ance. Overall data and trial management will be pro-
vided by the Clinical Trials Research Unit (CTRU)
(University of Leeds, UK) where received data will be
monitored for quality and completeness. Any missing
data will be pursued until it is received, confirmed as
not available or the trial is at analysis.
The independent DMEC will review the safety and
ethics of the trial. Detailed un-blinded reports will be
prepared by the CTRU for the DMEC at approximately
yearly intervals. These reports will include summaries of
recruitment, toxicity (rates of occurrences of AEs, SAEs,
SARs and SUSARs) progression, strategy failure events
and overall survival by treatment group. A formal in-
terim analysis will be reported to the DMEC after the
end of stages A and B (21 months after the start of re-
cruitment). A report will be prepared and presented to
the DMEC on the interim recruitment rates and early ef-
ficacy data (TSF).
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Quality of life is a major consideration in care of people
with RCC and is a key component of this trial, which
aims to explore the impact on QoL of a DFIS strategy
compared to a CCS. The use of averaged QALY as a co-
primary endpoint of the trial exemplifies the importance
of this. QoL will be assessed with the following question-
naires: FACT-G (28 items in four domains) [18], the
FKSI-15 (15 items) [19] and the EuroQol instrument (in-
cluding EQ-5DTM descriptive system and the EQ visual
analogue scale, EQ-VAS) [20].
Extensive QoL data were collected as part of the pi-
votal sunitinib trial programme [21,22], including both
generic measures (FACT-G, EQ-5DTM/EQ-VAS) and
disease-specific measures (FKSI-15 and FKSI-DRS sub-
scale), but the reporting of the EQ-5DTM/EQ-VAS data
in the publication was restricted to baseline mean and
standard deviations (sd) and modelled average for all fol-
low-up. In addition, QoL data from patients who
stopped treatment were not included in the analysis. As
a result these data are of limited use for estimating the
QALY gains from a sunitinib DFIS strategy in the NHS.
A small Japanese trial [23] reported baseline and follow-
up EQ-VAS data for day 1 and day 28 of each treatment
cycle. These data, plotted graphically, show a sawtooth
pattern of QoL whilst taking sunitinib, with highest mea-
sures on day 1 and lowest measures on day 28, consistent
with clinical experience. The authors report that the same
pattern was seen in the EQ-5DTM data, providing reassur-
ance that both these instruments will be sensitive to iden-
tify the hypothesised benefit. This intra-cycle variability
necessitates frequent QoL measures to accurately capture
the information required and hence to maximise the op-
portunity to identify any QoL/QALY differences between
the arms. This drives the timings of QoL data collection.
Information will be collected at clinic visits at baseline,
and day 1 of sunitinib cycle 1, 2, 3 and 4. Administration
in clinic will enable patients to be supported in their
completion, if required, prior to initiation of postal ques-
tionnaires. After this timepoint EQ-5DTM/EQ-VAS infor-
mation (a simple 2 page assessment) will be completed
every 2 weeks by patients at home, over 18 weeks. At cli-
nical assessment visits the FSKI and FACT-G will continue
to be completed 6 weekly. It is the period when CCS arm
patients continue treatment and most patients on the
DFIS arm stop treatment (i.e. after 6 months), when QoL
differences are predicted to be greatest and hence this is
when QoL data collection is most intensive. After the in-
tensive collection has finished, collection of all information
(including EQ-5D/VAS) will revert to 6 weekly in clinic.
Health economics
The relative cost-effectiveness of a sunitinib DFIS com-
pared to a sunitinib CCS is another important endpointin the STAR trial. Treatment strategies that reduce the
total quantity of sunitinib administered whilst maintain-
ing total health gain are likely to be significantly more
cost-effective than the current standard treatment stra-
tegy, thus supporting the DFIS model. The potential
QoL gains along with the potential reduced rates of ad-
verse events due to treatment interruption make the use
of a DFIS strategy worthy of additional investigation as a
cost-saving strategy.
To enable a comprehensive cost-effectiveness analysis,
information will be collected on community, primary,
secondary and tertiary health care utilisation and third
sector care of participants. This will be collected via
MRU questionnaires and CRFs at each clinical review.
The economic evaluation will consider both the NHS
and Personal Social Services (PSS) perspective and a so-
cietal perspective. The latter will include out-of-pocket
expenses, and the productivity costs to the patients and
formal and informal care providers. The analysis will es-
timate the expected incremental cost per QALY of a
sunitinib DFIS compared to a sunitinib CCS.
The extensive QoL data collected in this trial repre-
sents a unique source of information valuing health at
every point of time. Using each follow-up collection
point, the distribution QALY gains will be precisely plot-
ted over time and compared between the two arms (co-
primary endpoint of the overall trial). There is uncertainty
regarding the utilities of different health states in advanced
RCC; i.e. the value of ‘Q’ in the QALY, for example NICE
report a range for utility values 0.6 to 0.8 for stable/
progression free disease states [4,24]. The results of this
trial will answer questions about the risks and benefits of
structured treatment interruption (DFIS) and will hope-
fully allow robust conclusions to be drawn. The uncer-
tainty around the appropriate utilities for specific health
states will be examined within a probabilistic sensitivity
analysis and using scenario analyses where alternative EQ-
5D algorithms are used to attach utilities to specific health
states. An interim analysis between stages A/B and C of
the QALY data collected will be used to ensure the
assumptions used to power the trial on a QALY endpoint
are correct. The decision analytic cost effectiveness model
will also be used to estimate a value of information ana-
lysis (VoI) [25] and provide a methodological framework
that explicitly considers the uncertainty surrounding
the decision of a health care system to adopt a new
technology using the expected value of perfect informa-
tion (EVPI).Statistical methods and analysis
Statistical analysis will be the responsibility of the STAR
CTRU Trial Statistician. A full statistical analysis plan will
be written before any formal analyses are undertaken.
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the ITT and per protocol analysis populations. For the
superiority endpoints the ITT analysis will be given pri-
macy, however for the non-inferiority endpoints equal
weighting will be given to both the ITT analysis and the
per-protocol analysis, as the ITT is likely to be the least
conservative approach when testing for non-inferiority.
An overall two-sided 5% significance level will be used
for all superiority endpoint comparisons, and a one-
sided 2.5% significance level will be used for all non-
inferiority endpoints.
A formal interim analysis will take place after stages A
and B (at 21 months after the start of recruitment). A
feasibility and efficacy stopping rule have been specified
(as detailed below) to ensure the trial is stopped as early
as possible in the case of insufficient recruitment (Stage
A) or insufficient efficacy (Stage B) in the DFIS arm. The
DMEC in light of this interim data will make their
recommendations to the Trial Steering Committee who
will in turn decide whether the trial can continue to
Stage C.
Stage A
An essential part of any trial is ensuring that recruitment
targets are met. This is formalised in the STAR trial, to
ensure that the results can be delivered to time and tar-
get. To do this the recruitment per month during
months 10–21 (inclusive) of recruitment will be deter-
mined; not utilising the initial 9 months which are
allowed to enable site set up and familiarity with the
trial. To continue the trial, a specific recruitment rate
must be attained. The 95% CI for a recruitment rate of
one patient per centre per month, with 13 centres for
12 months, is .85-1.15. Therefore a minimum of 0.85
patients per centre open and recruiting per month
would be required i.e. 133 patients recruited over the
12 month period, assuming all 13 centres opened and
commenced recruitment in a timely manner.
Stage B
An interim efficacy endpoint has been included to fur-
ther ensure the appropriateness of extending recruit-
ment and continuing the trial to stage C. PFS is not an
appropriate comparator endpoint in the trial as, due to
planned treatment breaks, the initial PFS is likely to be
shorter in the DFIS arm compared to the CCS arm. TSF
will be analysed (targeted to look at differences in
15 months strategy failure rates) in both arms and non-
inferiority will be required to be demonstrated between
the arms for the trial to continue to stage C. The TSF in
the DFIS arm must be less than 15% worse than in the
CCS arm (strategy failure assumed to be 80% at
15 months). Assuming 21 months of accrual and imme-
diate analysis, 80% power, and assuming proportionalhazards, this would require 67 events and a population
of 112 patients (56 in each arm; approximately 53% of
the 210 in total that will be randomised) who take up
their randomisation at 6 months.
During the formal interim analysis, an analysis of the
utility data so far obtained will also be performed to re-
vise the estimates of the power to detect the composite
QALY endpoint and to evaluate possible refinements in
the trial design as a result.Stage C
There are two co-primary outcome measures: OS and
averaged QALY. The two null hypotheses are that DFIS
is not inferior to CCS in terms of OS and QALYs. To
calculate a sample size for the primary OS endpoint, a
difference of ≤7.5% in OS at two years between the two
arms has been assumed to be an acceptable non-
inferiority margin (equivalent to a hazard ratio of 0.806).
To demonstrate this non-inferiority with 80% power will
require the recruitment of approximately 1000 patients
(allowing for 10% of patients being lost to follow-up). To
calculate a sample size for the primary QALY endpoint a
difference of ≤10% in mean QALYs between the two
arms has been assumed to be an acceptable non-
inferiority margin. While it is hoped that survival will be
equivalent between the two arms, a slightly poorer sur-
vival in the DFIS arm would be acceptable if offset by a
significant QoL gain in these patients, this will be cap-
tured through the QALY measure. With a hazard ratio
of 0.9 in favour of CCS and 1000 patients recruited,
simulations give a power of 84% to show non-inferiority
in the QALY endpoint. Both non-inferiority sample sizes
are calculated assuming a 1-sided 97.5% confidence
interval, as described by Kay [26], and assuming patients
are recruited in total over 4.5 years, with a further
follow-up of 2 years before evaluating the data.
For Stage B TSF and Stage C OS endpoints, the pri-
mary analysis will comprise Kaplan-Meier curves includ-
ing those adjusted for the minimisation factors [27],
giving 95% CIs for the TSF and 2-year survival differ-
ence. A a Cox proportional hazards model analysis
adjusting for minimisation factors and associated hazard
ratios plus 95% CIs for the DFIS vs. CCS comparisons
will be pesented, as appropriate for the non-inferiority
analysis. The analysis of primacy is the Cox model.
For the QALY endpoint mean differences in QALYs,
calculated via the EQ-5D, between the arms, with 95%
confidence limits, will be calculated. Multivariate linear
regression will be used to adjust for minimisation fac-
tors. If the data are not normally distributed, transfor-
mations to normality will be investigated. If no such
transformations can be found we will analyse the differ-
ence between median QALYs and we will calculate
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medians as described by Campbell and Gardner [28].
Trial organisation and administration
The STAR trial is funded by the NIHR Health Techno-
logy Assessment programme (Grant ref 09/91/21). The
trial is sponsored by the University of Leeds and was
developed by the STAR trial management group and me-
dical advisory group, with the support of the UK NCRI
Renal Clinical Studies Group. The trial is registered
(ISRCTN06473203 EudraCT number 2011-001098-16).
Trial supervision will be established according to the
principles of Good Clinical Practice (GCP) and in line
with the relevant Research Governance Framework
within the UK and through adherence with CTRU
standard operating procedures (SOP). The trial will be
performed in accordance with the recommendations
guiding physicians in biomedical research involving
human subjects adopted by the 18th World Medical As-
sembly, Helsinki, Finland, 1964, amended at the 52nd
World Medical Association General Assembly, Edinburgh,
Scotland, October 2000. Ethical approval in the UK has
been obtained through the National Research Ethics Ser-
vice (ref 11/NW/0246).
A core Internal Project Team, Trial Management
Group (TMG), a Trial Steering Committee (TSC) and
DMEC will be established. The independent DMEC will
be appointed to review the safety and ethics of the trial,
alongside trial progress and the overall direction as over-
seen by the TSC. Interim reports will be presented to
the DMEC, in strict confidence, at, at least, yearly inter-
vals. This committee, in light of the interim data, and of
any advice or evidence they wish to request, will advise
the TSC if there is proof beyond reasonable doubt that
one treatment strategy is better.
Ancilliary studies
Patient preference and understanding study
There is an integral qualitative substudy in two parts
which aims to investigate patient’s reasons for entering
or declining entry into the STAR trial. The reasons why,
and under what conditions, patients participate in cli-
nical trials is an under-researched and poorly under-
stood area, especially in clinical trials in advanced
cancer. Nevertheless, the reasons for non-participation
are frequently related to how the healthcare profes-
sionals involved present the design and objectives of the
clinical trial to the patient, and how the patient assimi-
lates this information. It is therefore of importance to
understand how patients accept the information about
potential participation in a particular clinical trial and
what their experiences are of information provision re-
lating to the trial. The perspectives of patients as poten-
tial users have become an essential part of determiningclinical utility of drugs and/or procedures yet patients’
perspectives on being involved in clinical trials are a se-
verely under-researched area.
It is anticipated that this trial will be complex to dis-
cuss with patients, who may have reservations and
strong feelings about stopping a treatment that they
know to be working. There is only limited guidance from
the literature regarding how optimally to present this trial
to patients as evidence available will be either too generic,
or too specific for the individual trial investigated.
This substudy aims to conduct qualitative semi-
structured interviews with up to 50 patients from three
clinical research sites with different catchment patterns
to increase the diversity of the sample. Twenty-five
patients who have declined to participate in the STAR
trial and 25 STAR participants randomised to the DFIS
arm will be included. The patients who have declined
participation will be interviewed to investigate their rea-
sons for declining trial entry. The DFIS participants will
be interviewed to investigate their feelings about stop-
ping sunitinib, but also the reasons which led them to
initially participate. All interviews will be audio-recorded
and professionally transcribed verbatim. The analysis will
adopt thematic approach.
Information gained will be utilised to optimise patient
information provided relating to the study (audiovisual
and PIS) and to inform clinical staff regarding preferred
methods of describing the study, which ideally will en-
able recruitment to be maximised in stage C of the
study. Other studies (e.g. the ProtecT study which ran-
domised patients with localised prostate cancer to sur-
gery, radiotherapy or active monitoring) have confirmed
the value of such approaches in improving recruitment
and taking up of randomisation [29].
Translational studies
Translational research studies are planned to investigate
blood and/or tissue markers of sunitinib response and
toxicity, and imaging markers to identify earlier evidence
of disease response or progression. Imaging sub-studies
include an optional CT study and an optional MRI study.
Discussion
This has been a challenging trial to design, however the
design is applicable to many other treatment strategies
using different drugs and in different disease areas. Non-
standard endpoints were required due to the intermit-
tent nature of the DFIS; as PFS was not an appropriate
key intermediary endpoint, TSF was defined and
selected. Similar composite endpoints have been used in
the previous intermittent chemotherapy CRC trials, and
equivalent endpoints in intermittent therapy trials of
anti-retrovirals in the treatment of HIV and of antipsy-
chotics in Alzheimer’s disease.
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(VotrientTM, GSK), another TKI which works via the
same mechanism as sunitinib. In the UK it has recently
been recommended by NICE as an alternative first-line
treatment option for patients with advanced RCC, con-
ditional on pricing. Evidence is awaited regarding the ef-
ficacy of pazopanib compared to that of sunitinib in the
first-line setting of advanced RCC (the COMPARZ trial).
Based on the available evidence when designing the trial
sunitinib is currently the only drug permitted for use in
stages A/B of the STAR trial. When data becomes avail-
able from the COMPARZ trial, a decision will be made
as to whether eligibility will be extended to patients trea-
ted with pazopanib. If pazopanib is permitted, then an
additional minimisation factor will be required, as well
as a recalculation of the QALY powering of the trial.
The STAR study will be an important trial. Che-
motherapeutic agents have often necessitated restricted
periods of treatment due to toxicity, but this is not ne-
cessarily true of novel targeted therapies. However,
chronic minor side effects such as fatigue can have cu-
mulative major effects on QoL, particularly over longer
periods of time. Conflicting pressures exist when estab-
lishing a treatment duration, pharmaceutical companies
have an interest in prolonged treatment durations, until
disease progression or even beyond, but it is usually in
the patient’s and healthcare provider’s best interest to
use shorter durations of treatment, in terms of toxicity,
QoL and cost effectiveness. If successful, the STAR trial
design could be easily adapted for use with other sys-
temic anti-cancer therapies in other disease sites. We
predict that trial designs such as this will become increas-
ingly utilised in the future, as they allow for incorporation
of more complex treatment strategies alongside emphasis-
ing the importance of quality as well as quantity of life for
patients.
Endnotes
aTSF is defined as the time from randomisation until
death; disease progression on sunitinib; disease progres-
sion in the DFIS arm during a planned treatment break
assuming no further disease response or stabilisation on
subsequent sunitinib occurs; participant requires use of
a new systemic anti-cancer agent for RCC or significant
clinical deterioration where deterioration is assumed to
be due to renal cancer progression and not another
comorbidity and deterioration sufficient to warrant ces-
sation of sunitinib if on treatment or to preclude restart-
ing sunitinib if on a treatment break on the DFIS arm,
without it being clinicially appropriate to arrange radio-
logical confirmation of the progression
bSPFI is defined as the sum of the intervals from the
start of each treatment block with sunitinib, until radio-
logical evidence of disease progression provided therehas been some evidence of disease control prior to on-
going progression
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